A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma

Hugo J. A. Adams; Thomas C. Kwee

doi:10.1200/JCO.18.01830

A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma

Hugo J. A. Adams^*, Thomas C. Kwee

^*Corresponding author for this work

Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Research output: Contribution to journal › Letter › Academic › peer-review

2 Citations (Scopus)

52 Downloads (Pure)

Original language	English
Pages (from-to)	852-854
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	37
Issue number	10
DOIs	https://doi.org/10.1200/JCO.18.01830
Publication status	Published - 1-Apr-2019

Keywords

RESPONSE ASSESSMENT
INTERIM

Access to Document

10.1200/JCO.18.01830

A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin LymphomaFinal publisher's version, 460 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{d14920aa524c44e98286979ca1bc7115,

title = "A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma",

keywords = "RESPONSE ASSESSMENT, INTERIM",

author = "Adams, {Hugo J. A.} and Kwee, {Thomas C.}",

year = "2019",

month = apr,

day = "1",

doi = "10.1200/JCO.18.01830",

language = "English",

volume = "37",

pages = "852--854",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "AMER SOC CLINICAL ONCOLOGY",

number = "10",

}

TY - JOUR

T1 - A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma

AU - Adams, Hugo J. A.

AU - Kwee, Thomas C.

PY - 2019/4/1

Y1 - 2019/4/1

KW - RESPONSE ASSESSMENT

KW - INTERIM

U2 - 10.1200/JCO.18.01830

DO - 10.1200/JCO.18.01830

M3 - Letter

SN - 0732-183X

VL - 37

SP - 852

EP - 854

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 10

ER -